The makers of obesity drug Wegovy have submitted a full request to the HSE for it to be covered on medical cards and other drug payment schemes. Pharmaceutical company Novo Nordisk, which also makes Ozempic, began the assessment last year and earlier this week made its final submission. A Novo Nordisk spokeswoman in Ireland described this week’s development as “a milestone in progressing this reimbursement application”. It applied for Wegovy to be covered for patients under the State’s medical card and community drug schemes. The Novo Nordisk spokeswoman said it works closely with the HPRA to “raise awareness about and combat the manufacturing and spread of unauthorised, unlawful and unsafe semaglutide active pharmaceutical ingredients (APIs) and semaglutide medicines”.

Source: Irish Examiner February 28, 2026 00:36 UTC